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This study investigates the efficacy of diphenyl diselenide [(PhSe)2] in attenuating methylmercury- (MeHg-)induced toxicity in
rats. Adult rats were treated with MeHg [5 mg/kg/day, intragastrically (i.g.)] and/ or (PhSe)2 [1 mg/kg/day, intraperitoneally (i.p.)]
for 21 days. Body weight gain and motor deficits were evaluated prior to treatment, on treatment days 11 and 21. In addition,
hepaticandcerebralmitochondrialfunction(reactiveoxygenspecies(ROS)formation,totalandnonproteinthiollevels,membrane
potential (ΔΨm), metabolic function, and swelling), hepatic, cerebral, and muscular mercury levels, and hepatic, cerebral, and
renal thioredoxin reductase (TrxR) activity were evaluated. MeHg caused hepatic and cerebral mitochondrial dysfunction and
inhibitedTrxRactivityinliver(38,9%),brain(64,3%),andkidney(73,8%).Cotreatmentwith(PhSe)2 protectedhepaticandcerebral
mitochondrialthiolsfromdepletionbyMeHgbutfailedtocompletelyreverseMeHg’seffectonhepaticandcerebralmitochondrial
dysfunction or hepatic, cerebral, and renal inhibition of TrxR activity. Additionally, the cotreatment with (PhSe)2 increased Hg
accumulation in the liver (50,5%) and brain (49,4%) and increased the MeHg-induced motor deficits and body-weight loss. In
conclusion, these results indicate that (PhSe)2 can increase Hg body burden as well as the neurotoxic effects induced by MeHg
exposure in rats.
1. Introduction
MeHg is one of the most poisonous environmental contam-
inants, causing toxic effects in humans and experimental
animals [1, 2]. Environmental MeHg is largely derived from
inorganic mercury biomethylation carried out primarily by
aquaticmicroorganisms[3]withsubsequentaccumulationin
the aquatic food chain and human consumption [4]. MeHg
causes acute and chronic damage to multiple organs, most
profoundly to the central nervous system (CNS), in partic-
ular when exposures occur during the neurodevelopmental
period [1, 5, 6].
The events that mediate MeHg toxicity are largely depen-
dent upon its electrophilic properties, which allow for its2 BioMed Research International
interaction with soft nucleophilic groups (mainly thiols
and selenols) from either low- or high-molecular-weight
biomolecules [7]. The interaction of MeHg with soft nucle-
ophilic groups from biomolecules is responsible, at least in
part, for decreased antioxidant capacity and increased ROS
generation [7, 8]. Notably, MeHg can disrupt the activity of
thiol- and selenol-containing proteins, such as glutathione
peroxidase (GPx), thioredoxin (Trx), and TrxR [1, 9–11].
These proteins are important components of the cellular
antioxidant system, and their inhibition contributes to the
disruption of the normal redox balance of cells [7].
In addition, MeHg can disrupt mitochondrial function
by targeting specific thiol-containing proteins, including
respiratory chain complexes [12, 13]. The inhibition of these
complexesorenzymescancontributetomitochondrialdepo-
larization and swelling upon MeHg exposure. Mitochondrial
targeting by MeHg has also been associated with increased
mitochondrialROSgeneration,whichcanfurtherexacerbate
thetoxicityofMeHgbyattackingadditionalnucleophiliccen-
ters in mitochondria and in other subcellular compartments
[7, 10, 12–14], leading to a vicious cycle of cell demise.
Several studies demonstrated that organic and inorganic
selenium (Se) compounds influence the deposition and
toxicity of MeHg [13, 15, 16]. Se is an essential trace element
for a wide range of living organisms, including humans [17].
Se is necessary for the expression of approximately 25 Se-
dependent proteins, including GPx, TrxR, and several other
enzymesandproteins,whichcanmodulatethecellularredox
and antioxidant status [17].
In addition to inorganic and naturally occurring organo-
seleniumcompounds,syntheticorganoseleniumcompounds
canalsoexhibitprotectiveeffectsagainstMeHg.Forexample,
ebselen and (PhSe)2 have been shown to exert beneficial
effectsagainstinvitroandinvivoMeHg-inducedtoxicity[18–
21]. (PhSe)2 (which is the simplest of the diaryl diselenides
[22]) protected against an array of toxic effects of MeHg and
loweredtheHgburdeninthebrain,liver,andkidneysofadult
mice[21].Themolecularmechanism(s)whichunderlie(s)the
protective effects of (PhSe)2 in mice likely reflect the direct
interaction of MeHg with “selenol intermediate” of (PhSe)2
after its reaction with thiols, or indirectly, by modulating
oxidative stress levels [21, 23]. In short, the protective effects
of (PhSe)2 against MeHg-induced toxicity are likely related
to its antioxidant properties and its ability to form stable
complexes with MeHg, which can increase Hg excretion and
decrease the MeHg body burden.
Of particular pharmacological significance, the toxicity
and pharmacokinetics of MeHg [24] are different in mice
and rat which can be explained by the higher binding affinity
of rat hemoglobin, which contains more cysteinyl residues
than mice protein, for MeHg when compared to the mice
hemoglobin [25]. (PhSe)2 toxicity and pharmacokinetics
differences between mice and rat also exist and could be
explained by a faster metabolization of (PhSe)2 in mice [26–
28].
Therefore, the aim of the present study was to investigate
the potential protective effects of (PhSe)2 against MeHg-
induced toxicity and mitochondrial dysfunction in rats. To
accomplish this goal, the effects of (PhSe)2 on Hg deposition
in liver and brain and on behavioral and biochemical param-
eters were studied in rats.
2. Materials and Methods
2.1. Chemicals. Chemicals, including ethylene glycol-bis(𝗽-
aminoethylether)-N,N,N
򸀠,N
򸀠-tetraacetic acid (EGTA), 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
2,4 dinitrophenol (2,4 DNP), 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), glutamic acid,
safranin O, 2
򸀠,7
򸀠-dichlorofluorescin diacetate (H2-DCFDA),
and methylmercury chloride were obtained from Sigma
Aldrich (St. Louis, MO, USA). (PhSe)2 was synthesized
according to the method by Paulmier [29]. All other chemi-
calswereofanalyticalreagentgradeandpurchasedfromlocal
commercial suppliers.
2.2. Animals. Male Wistar rats, weighing 250–310g and with
age from 3 to 3.5 months, from our own breeding colony
were kept in cages (four animals in each). Rats were placed
in a room with controlled temperature (22 ± 3
∘C) on a 12h
light/dark cycle (lights on at 7:00 a.m.) and had continuous
access to food and water. All experiments were conducted
in accordance with the Committee on Care and Use of
Experimental Animal Resources of the Federal University of
Santa Maria, Brazil.
2.3. Treatment. Sixteen rats were equally divided into four
experimental groups as follows: (1) control (10mL/Kg of
water i.g. and 1mL/Kg of soybean oil i.p.); (2) (PhSe)2
(10mL/Kgofwateri.g.and1mg/Kgof(PhSe)2 i.p.);(3)MeHg
(5mg/Kg of MeHg i.g. and 1mL/Kg of soybean oil i.p.); and
(4) (PhSe)2 + MeHg (5mg/Kg of MeHg i.g. and 1mg/Kg
of (PhSe)2 i.p.). Based on previous studies, exposures were
performeddailyovera21-dayperiod[21,30,31].Twenty-four
hours after the last exposure, the animals were sacrificed and
the livers, brains, kidneys, and skeletal muscle were quickly
removed, placed on ice and homogenized.
2.4. Determination of Hg Levels. Tissue levels of total Hg
were measured in liver, brain, and skeletal muscle collected
at the time of euthanasia [32]. Approximately 0.4g (wet
weight) of the tissues was weighed and digested with 5mL
of HNO3 acid(65%).Digestedsamplesweredilutedto50mL
with ultrapure water before analysis using a Multitype ICP
Emission Spectrometer (ICPE-9000, Shimadzu). Calibration
standard curve was prepared freshly using mercury stock
standard solution.
2.5. Motor Coordination Tests
2.5.1. Open Field Test. General locomotor activity was eval-
uated as previously described [33]. The number of line
crossings (number of segments crossed with the four paws)
and rearings was measured over 5min and taken as an
indicator of locomotor activity. The test was carried out at
3 time points: 24 hours prior to treatment (basal), and on
treatment days 11 and 21.BioMed Research International 3
2.5.2. Rotarod Test. Motor coordination was tested on the
rotarod apparatus as described previously [34, 35]. The
latencytofallandthenumberoffallsfromtheapparatuswere
recordedfor120s.Thetestswereconducted3times:24hours
prior to treatment (basal), and on treatment days 11 and 21.
2.6. TrxR
2.6.1. TrxR Purification. TrxR was partially purified by a
modification of the method by Holmgren and Bjornstedt
[36]. Tissues were homogenized in buffered saline (137mM
NaCl, 2.7mM KCl, 4.3mM Na2HPO4,a n d1 . 4m MK H 2PO4,
pH7.3).Livers,brains,andkidneys(0.5g)werehomogenized
i n1 0 ,3 ,a n d5v o l u m e so fb u ff e r e ds a l i n e ,r e s p e c t i v e l y .
Homogenates were centrifuged at 13,000g for 30min. The
protein concentration in the supernatant was measured and
adjusted to 10mg/mL. The supernatant was dialyzed against
buffered saline for 16h to remove endogenous glutathione
(GSH) and Trx. The dialysate was heated at 55
∘Cf o r1 0m i n ,
cooled, and centrifuged at 13,000g for 30min to remove
denatured protein.
2.6.2. TrxR Activity. TrxR activity was measured by the
method of Holmgren and Bjornstedt [36]. The reaction
mixture consisted of the following: 0.24mM NADPH,
10mM EDTA, 100mM potassium phosphate buffer (pH 7.0),
2mg/mL 5,5
򸀠 dithiobis-2-nitrobenzoic acid (DTNB), and
0.2mg/mL of BSA. The partially purified TrxR was added
(to final concentration of 6–8𝜇go fp r o t e i n )t ot h ec u v e t t e
containing the reaction mixture, and the absorbance was
followed at 412nm for a maximum of 4min.
2.7. Isolation of Rat Brain and Liver Mitochondria. Rat brain
and liver mitochondria were isolated as previously described
byBrustovetskyandDubinsky[37],withsomemodifications.
Brainandliverwererapidlyweighedandhomogenizedin1:5
(w/v) ice-cold “isolation buffer I” containing 225mM man-
nitol, 75mM sucrose, 1mM K
+-EGTA, 0.1% bovine serum
albumin(BSA),and10mMK
+-HEPES,pH7 .2.Thetissuewas
then manually homogenized with a potter glass. The result-
ing suspension was centrifuged for 7min at 2,000g. After
centrifugation the supernatant was recentrifuged for 10min
at 12,000g. The pellet was resuspended in “isolation buffer
II” containing 225mM mannitol, 75mM sucrose, 1mM K
+-
EGTA, and 10mM K
+-HEPES pH 7.2 and recentrifuged
at 12,000g for 10min. The supernatant was discarded and
the final pellet gently washed and resuspended in “isolation
buffer II” without EGTA.
2.8.MitochondrialNonproteinandTotalThiolContent. Mito-
chondrial nonprotein and total thiol content were measured
according to the method of Ellman [38]. To determine total
thiol groups, mitochondria (0.3mg protein) were added to
the reaction medium containing 10mM Tris-HCl pH 7.2, 1%
SDS, and 10mM DTNB. Nonprotein thiol content was mea-
suredbyadding50𝜇L10%TCAto50𝜇Lofthemitochondria
(0.3mg protein). After centrifugation (4,000×ga t4
∘Cf o r
10min), the protein pellet was discarded and an aliquot of
the clear supernatant, neutralized with 0.1M NaOH, was
added to the medium containing 10mM Tris-HCl pH 7.2
and 10mM DTNB. The samples absorbance was measured
spectrophotometrically at a wavelength of 412nm.
2.9. Measurements of Mitochondrial ΔΨm. Mitochondrial
ΔΨm was estimated by fluorescence changes in safranin
O (3mM) recorded by RF-5301 Shimadzu spectrofluorom-
eter (Kyoto, Japan) operating at excitation and emission
wavelengths of 495 and 535nm, with slit widths of 1.5nm
[39]. Data on ΔΨm in the figures is presented in Arbitrary
Fluorescence Units (AFU).
2.10. Estimation of ROS Production. The mitochondrial
generation of ROS was determined spectrofluorimetrically,
using the membrane permeable fluorescent dye H2-DCFDA
recorded by RF-5301 Shimadzu spectrofluorometer (Kyoto,
Japan) operating at excitation and emission wavelengths of
488 and 525nm, with slit widths of 3nm [40]. Data of
ROS production in the figures is presented as Arbitrary
Fluorescence Units (AFU).
2.11. Assessment of Mitochondrial Metabolic Function. The
mitochondrial metabolic function was assessed by the con-
version of MTT to a dark violet formazan product by mito-
chondrial dehydrogenases [41]. The rate of MTT reduction
was measured spectrophotometrically at a wavelength of
570nm. Results were expressed as the percentage of MTT
r e d u c t i o nr e l a t i v et oc o n t r o lv a l u e s .
2.12. Assessment of Mitochondrial Swelling. Measurement of
mitochondrial swelling was performed in a RF-5301 Shi-
madzu spectrofluorometer at 600nm (slit 1.5nm for exci-
tation and emission) [42]. Data for mitochondrial swelling
are expressed as Arbitrary Absorbance Units (AAU). The
difference (ΔA) between the initial absorbance reading and
t h efi n a la b s o r b a n c er e a d i n gw a su s e df o rs t a t i s t i c a la n a l y s i s .
2.13. Protein Measurement. Protein was assayed by the
method of Bradford [43]w i t hb o v i n es e r u ma l b u m i na s
standard.
2.14. Statistical Analysis. Normality assumption was tested
with Kolmogorov-Smirnov test and the distribution of the
majority of results is not normal. Data were analyzed sta-
tistically by Mann-Whitney or Kruskal-Wallis, followed by
Dunn’s post-hoc tests when appropriate. The results were
considered statistically significant at 𝑃 < 0.05.A l ls t a t i s t i c a l
analyses were conducted using GraphPad Prism 5 (Version
5.01, GraphPad Software, Inc., USA).
3. Results
3.1. Effects of (PhSe)2 and MeHg on Body Weight. Treatment
with MeHg led to body-weight loss from the second week
until the end of the treatment compared to controls (𝑃<
0.05, Figure 1). Rats cotreated with (PhSe)2 and MeHg also4 BioMed Research International
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Figure1:EffectofMeHgand/or(PhSe)2 onthebodyweightgainin
adult rats. Data are expressed as mean ± S.D., 𝑛=4 .( ∗)r e p r e s e n t s
𝑃 < 0.05 as compared to controls by Mann-Whitney test.
showed a decrease in the body weight when compared to
the control group (𝑃 < 0.05, Figure 1). Rats treated with
(PhSe)2 lost weight after the first week of treatment (𝑃<
0.05) but showed a trend towards a recovery and were
statistically indistinguishable from the controls at the end of
the treatment (Figure 1).
3.2.Effectsof(PhSe)2 andM eH gonH gDeposition. Treatment
with MeHg increased the levels of Hg in liver, brain, and
skeletal muscle compared with controls (𝑃 < 0.05, Figure 2).
The cotreatment with (PhSe)2 caused a greater increase
in brain Hg deposition when compared to MeHg alone
treatment,bothinbrain(Figure 2(b))a n dl i v e r( Figure 2(a)),
and showed a trend towards increased deposition in skeletal
muscle (Figure 2(c)).
3.3. Effects of (PhSe)2 and MeHg on Motor Coordination
and Spontaneous Locomotor Activity. The effects of MeHg
and/or (PhSe)2 on locomotion and motor coordination were
assessed by the open-field and rotarod tests, respectively.
After 11 days, rats treated with MeHg showed increased
number of falls on the rotarod and decreased latency to the
first fall when compared to controls (𝑃 < 0.05,F i g u r e s3(a)
and 3(b)). Rats treatedwith(PhSe)2 did not show statistically
significant differences on the rotarod test when compared
to controls; however, rats cotreated with (PhSe)2 and MeHg
showed increased loss of motor coordinationas evidenced by
increased number of falls and reduced latency to the first fall
(𝑃 < 0.05,F i g u r e s3(a) and 3(b)). The rotarod test could not
be performed at the end of the treatment in rats receiving
M e H gs i n c et h e yw e r eu n a b l et or e m a i ni nt h ea p p a r a t u sd u e
to severe motor impairment caused by MeHg.
RatstreatedwithMeHgshowedadecreaseinthenumber
of crossings and rearings in the open-field at the end of the
treatment compared to the control rats (𝑃 < 0.05,F i g u r e s
3(c) and 3(d)). Rats cotreated with MeHg and (PhSe)2 also
showed a significant decrease in the number of crossings
after 11 days of treatment and a decrease in the number of
rearings at the end of the treatment (𝑃 < 0.05, Figure 3(d)).
Treatment with (PhSe)2 didnotaffecttherats’performancein
the open-field. The decrease in the number of crossings and
rearings observed in all groups on treatment days 11 and 21
was expected given that the animals habituate to the open-
field arena [44].
3.4. Effects of (PhSe)2 and MeHg on
Mitochondrial Dysfunction
3.4.1. Mitochondrial Metabolic Function. The hepatic mito-
chondrialmetabolicintegrity(MTTreduction)wasnotaffec-
ted by MeHg and/or (PhSe)2 (Figure 4(a)). Treatment with
MeHg or cotreatment with MeHg and (PhSe)2 decreased the
capacity of brain mitochondrial dehydrogenases to reduce
MTT compared to controls (𝑃 < 0.05, Figure 4(b)). Treat-
ment with (PhSe)2 a l o n ed i dn o ta ff e c tt h ec e r e b r a lm i t o -
chondrial metabolic function.
3.4.2. Mitochondrial Total and Nonprotein Thiols. MeHg
treatment decreased the total mitochondrial thiol levels in
b r a i na n dl i v e rw h e nc o m p a r e dt oc o n t r o l s( 𝑃 < 0.05,
Figure 5). Treatment with (PhSe)2 alone did not alter the
mitochondrial total thiol levels in liver and brain (Figure 5).
The cotreatment with (PhSe)2 blunted the MeHg-induced
mitochondrial total thiol level depletion in rats’ liver and
brain (𝑃 < 0.05, Figure 5). Rats treated with MeHg showed
decreased mitochondrial nonprotein thiol levels in the liver
compared to controls, and coadministration of (PhSe)2
blunted the MeHg-induced decrease in hepatic nonprotein
thiol content (𝑃 < 0.05, Figure 5(a)). Brain mitochondrial
nonprotein thiol levels were not affected by any of the
treatments (Figure 5(b)).
3.4.3. Mitochondrial Swelling. Treatment with MeHg sig-
nificantly increased hepatic mitochondrial swelling when
compared to controls (𝑃 < 0.05, Figure 6(a)). Cotreatment
with (PhSe)2 partially prevented the MeHg-induced mito-
chondrial swelling in liver (Figure 6(a)). Similarly, treatment
with MeHg showed a trend towards increased mitochondrial
swelling in brain (Figure 6(b)). The cotreatment with MeHg
and (PhSe)2 significantly increased cerebral mitochondrial
swelling when compared to controls (𝑃 < 0.05, Figure 6(b)).
Treatment with (PhSe)2 alonedidnotalterthemitochondrial
swelling in brain or liver compared to the controls (Figures
6(a) and 6(b)).
3.4.4. Mitochondrial ROS Production. Mitochondrial ROS
production (DCFH oxidation) was significantly increased in
livers of rats treated with MeHg or cotreated with MeHg and
(PhSe)2 (𝑃 < 0.05, Figure 7(a)). Rats treated with (PhSe)2
showed hepatic mitochondrial ROS levels indistinguishable
from controls. ROS productionin cerebral mitochondriawas
not affected by any of the treatments (Figure 7(b)).
3.4.5.MitochondrialΔΨm. Polarization (ΔΨm)ofmitochon-
d r i af r o ml i v e ro fr a t sc o t r e a t e dw i t hM e H ga n d( P h S e ) 2BioMed Research International 5
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Figure2:Hgcontentinliver(a),brain(b),andmuscle(c)ofratsexposedtoMeHgand/or(PhSe)2.Dataareexpressedasmean±S.D.,𝑛=4 .
(∗)r e p r e s e n t s𝑃 < 0.05 as compared to controls by Mann-Whitney test. (#) represents 𝑃 < 0.05 as compared to MeHg by Mann-Whitney
test.
showed only a trend towards decreased (Figures 8(a) and
8(c)). Treatment with (PhSe)2 and MeHg alone did not cause
mitochondrialdepolarizationinliverofrats(Figures8(a)and
8(c)). Treatment with (PhSe)2 and/or MeHg had no effect on
mitochondrial ΔΨm in brain of rats (Figures 8(b) and 8(d)).
3.5. Effects of (PhSe)2 a n dM e H go nT r x RA c t i v i t y .MeHg
is known to inhibit TrxR activity both in vitro and in vivo
[1,9,11].(PhSe)2 treatmentsignificantlyincreasedrenalTrxR
activities when compared to controls (𝑃 < 0.05,F i g u r e s9(a)
and 9(b)). Hepatic and cerebral TrxR activity showed a trend
towards increased in rats treated with (PhSe)2 (Figure 9(c)).
MeHg treatment also led to significant inhibition of TrxR
in liver, kidney, and brain compared to controls (𝑃 < 0.05,
Figure 9). Cotreatment with (PhSe)2 failed to significantly
attenuatetheMeHg-inducedinhibitionofTrxRactivityinthe
liver, kidney, or brain (Figure 9).
4. Discussion
The present study investigated the efficacy of (PhSe)2,a n
organoselenium compound, in attenuating MeHg-induced
toxicity in rats. Our results established that MeHg decreased
body weight (Figure 1) and induced motor deficits (Figure 3)
as well hepatic and cerebral mitochondrial dysfunction (Fig-
ures 4(b), 5, 6(a),a n d7(a))a n di n h i b i t e dT r x Ra c t i v i t yi n
liver, brain, and kidney (Figure 9) in the rat. The cotreatment
with (PhSe)2 and MeHg increased Hg accumulation in the
liverandbrain(Figure 2).Furthermore,thecotreatmentwith
(PhSe)2 protected hepatic and cerebral mitochondrial thiols
from depletion by MeHg (Figure 5) but did not prevent
hepatic and cerebral mitochondrial dysfunction (Figures
4(b), 6(b),a n d7(a)) nor did it reverse the MeHg-induced
motordeficits(Figure 3),body-weightloss(Figure 1),andthe
MeHg-induced inhibition of TrxR activity in liver, brain, and
kidney (Figure 9).
Cotreatmentwith(PhSe)2 andMeHgincreasedHgdepo-
sition in the brain and liver of exposed rats (Figure 2).
These results differ from those of de Freitas et al. [21]w h e r e
(PhSe)2 led to a significant reduction in Hg concentrations
in brain, liver, and kidney of MeHg-exposed mice. The
discrepancies between the 2 studies may be attributed to
metabolic differences between the species and the route of
administration. The toxicity and pharmacokinetics of MeHg
[24] are different in mice and rat which can be explained6 BioMed Research International
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Figure 3: Rotarod and open field tests in rats exposed to MeHg and/or (PhSe)2. The number of falls (a) and latency for the first fall (b)
ambulation (crossing) (a) and rearing (b) were recorded. Data are expressed as mean ± S.D., 𝑛=4 .( ∗)r e p r e s e n t s𝑃 < 0.05 as compared to
controls by Kruskal-Wallis test followed by multiple comparison test. (#) represents 𝑃 < 0.05 as compared to (PhSe)2 by Kruskal-Wallis test
followed by multiple comparison test.
by the higher binding affinity of rat hemoglobin, containing
more cysteinyl residues, for MeHg when compared to the
mice hemoglobin [25]. (PhSe)2 toxicity and pharmacokinet-
ics differences between mice and rat also exist and could
be explained by a faster metabolization of (PhSe)2 in mice
[26–28]. Notably, herein rats were administered (PhSe)2 i.p.,
whilst in the study by de Freitas et al. [21]( P h S e ) 2 was
subcutaneously (s.c.) administered to the mice. Another
difference between the two works is in relation to the dose
of MeHg: in our study we used a dose 2.5 times higher than
in the study of de Freitas et al. (2mg/Kg). However, the
duration of the treatment was shorter in our study, 21 versus
35 days. On the other hand, the dose of (PhSe)2 was similar
betweenthetwostudies.ThehigherdoseofMeHgusedinour
studymayhavecontributedtothediscrepanciessinceitcould
generate a moresevere toxicity which couldnotbe prevented
by (PhSe)2. However, we realize that the differences in the
pharmacokinetics between rats and mice for the (PhSe)2 is
the major factor involved in the discrepancies found here
[28].
In the study by de Freitas et al. [21]t h ep r o p o s e d
mechanism for the reduction Hg’s organ burden by (PhSe)2
was the formation of a selenol/selenolate (PhSeH/PhSe
−)
intermediate, which could interact with MeHg, generating
the readily excretable PhSeHgMe complex. One possible
explanationfortheincreaseinhepaticandcerebralHgdepo-
sition (Figures 2(a) and 2(b), resp.) by the cotreatment with
(PhSe)2 observed herein may be the conversion of (PhSe)2
to inorganic selenium, which is subsequently metabolized
to selenhidric acid (HSe
−). HSe
− c o u l db i n dt oM e H gt o
form a less soluble complex [45], which can be degraded to
HgSe [46, 47]. In addition, Palmer and Parkin [48]s h o w e dBioMed Research International 7
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Figure 4: MTT reduction in liver (a) and brain (b) mitochondria of rats exposed to MeHg and/or (PhSe)2. Data are expressed as mean ±
S.D., 𝑛=4 .( ∗)r e p r e s e n t s𝑃 < 0.05 as compared to controls by Mann-Whitney test.
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Figure 5: Total and nonprotein thiol content in liver (a), (c) and brain (b), (d) mitochondria of rats exposed to MeHg and/or (PhSe)2.D a t a
are expressed as mean ± S.D., 𝑛=4 .( ∗)r e p r e s e n t s𝑃 < 0.05 as compared to controls by Mann-Whitney test.
that organoselenium can also form a complex with mercury.
Thus the increase in hepatic and cerebral Hg deposition
by the cotreatment with (PhSe)2 possibly involves Hg:Se
interactionsandtheformationofalessexcretablecompound
that accumulates in these organs [45]. These results are in
agreementwithotherstudiesthatshowedelevateddeposition
of Hg in key brain regions upon oral Se administration [49,
50] .I th a sb e e ns p e c u l a t e dt h a tt h ef o r m a t i o no fi n s o l u b l e
HgSesaltcouldreducethetoxicityofMeHg.However,exper-
imental evidence supporting this assumption has yet to be8 BioMed Research International
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Figure6:Mitochondrialswellinginliver(a)andbrain(b)ofratsexposedtoMeHgand/or(PhSe)2.Dataareexpressedasmean±S.D.,𝑛=4 .
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Figure 7: ROS production (H2-DCFH oxidation) in liver (a) and brain (b) mitochondria of rats exposed to MeHg and/or (PhSe)2.D a t aa r e
expressed as mean ± S.D., 𝑛=4 .( ∗)r e p r e s e n t s𝑃 < 0.05 as compared to controls by Mann-Whitney test.
generated. Although the cotreatment with (PhSe)2 increased
Hg levels in brain and liver, these were accompanied by
a partial protection against MeHg-induced mitochondrial
dysfunction. We suggest that the formation of an insoluble
and inert complex between Hg and Se could decrease the
availability of MeHg that could react with important cellular
components decreasing its toxicity.
Decreased weight gain and weight loss are prominent
and readily observed features of severe MeHg toxicity. In
this study, rats treated with MeHg showed body-weight
loss (Figure 1). Notably, the most severe effect on weight
loss occurred in rats cotreated with (PhSe)2 and MeHg
(Figure 1). In addition, rats treated with MeHg showed
decreased locomotor activity (Figure 3). Cotreatment with
(PhSe)2 a n dM e H gi n c r e a s e dt h es e v e r i t yo fm o t o rd y s f u n c -
tion (rotarod test) (Figure 3), likely as a result of increased
Hg deposition in the brain (Figure 2(b)). Motor deficits
are the most apparent neurological effects following MeHg
exposure [51]. In vivo studies in rodents point to impairment
in intracellular calcium homeostasis, alteration in glutamate
homeostasis, and oxidative stress as critical mediators of
MeHg-induced neurotoxicity [52]. The overactivation of
N-methyl-D-aspartate- (NMDA-) type glutamate receptors
increases Ca
2+ influx into neurons, thereby leading to cell
death[53].Alternatively,Ca
2+ takenupbymitochondriamay
stimulate the generation of ROS [54].
Several studies corroborate MeHg’s ability to induce
mitochondrial dysfunction and ROS generation [14, 18, 55].
The high affinity binding of MeHg to thiol groups inactivates
enzymes, including respiratory chain complexes [7, 13, 55],
decreasing mitochondrial dehydrogenases activity. Inhibi-
tion of these complexes may contribute to mitochondrial
swelling and ROS production after MeHg exposure (Figures
6 and 7). However, in brain, the MeHg-induced decrease in
mitochondrialdehydrogenasesactivity(MTTreduction)was
not accompanied by an increase in ROS production. TheseBioMed Research International 9
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Figure 8: Mitochondrial depolarization in liver (a), (c) and brain (b), (d) of rats exposed to MeHg and/or (PhSe)2. Figures (a) and (b) show
mitochondrial membrane potential (AFU). Figures (c) and (d) show mitochondrial ΔΨm. ΔΨm1 = delta of fluorescence before (time 0) and
after addition of mitochondria (time 150 seconds) and ΔΨm2 = delta of fluorescence before (time 150 seconds) and after addition of 2,4 DNP
(time 300 seconds). Data are expressed as mean ± S.D., 𝑛=4 .
results are corroborated by the fact that MeHg affected total
thiols but not nonprotein thiol levels in brain mitochondria.
MeHg caused a decrease in the total mitochondrial thiol
levels in brain, which is related mainly with protein thiols,
a n di si na g r e e m e n tw i t ht h ei n h i b i t i o no fm i t o c h o n d r i a l
dehydrogenases activity in this tissue. On the other hand,
MeHg did not affect nonprotein thiol levels (mainly GSH)
in brain mitochondria, which can explain the normal ROS
production, since GSH is the main antioxidant in brain.
The cotreatment with (PhSe)2 prevented the MeHg-
induced mitochondrial total and nonprotein thiol groups
depletion in the brain and liver (Figure 4). The efficacy of
(PhSe)2 in preventing thiol depletion may reside in its ability
to form a complex with MeHg, thus effectively reducing
MeHg binding to protein and free thiols. Treatment with
(PhSe)2 also partially protected the liver from mitochondrial
MeHg-induced swelling (Figure 6(a)). However, the cotreat-
ment with (PhSe)2 failed to reverse the MeHg-induced mito-
chondrial swelling (Figure 6(b))a n dd e c r e a s e dm i t o c h o n -
drial metabolic function (Figure 3(b))i nt h eb r a i na sw e l la s
increasedmitochondrialROSproduction(Figure 7(a))inthe
liver. These results indicate that mechanisms other than the
interaction with important free and protein thiols are likely
involved in the MeHg-induced mitochondrial dysfunction.
Thus, the preferential affinity of MeHg for specific, and as
of yet unidentified, mitochondrial protein targets may have
ac r i t i c a lr o l ei nM e H g ’ st o x i c i t y .
Previous studies have demonstrated that MeHg can
directly inhibit TrxR activity both in vitro and in vivo [1,
9, 11]. Mammalian TrxR is a selenoenzyme containing a10 BioMed Research International
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Figure9:TrxRactivityinliver(a),kidney(b),andbrain(c)ofratsexposedtoMeHgand/or(PhSe)2.Dataareexpressedasmean±S.D.,𝑛=4 .
(∗)r e p r e s e n t s𝑃 < 0.05 as compared to controls by Mann-Whitney test. (#) represents 𝑃 < 0.05 as compared to controls by Mann-Whitney
test.
unique, catalytically active selenolthiol/selenenylsulfide in
the conserved C-terminal sequence (-Gly-Cys-Sec-Gly) [56].
Three mammalian TrxR selenoenzymes have been identi-
fied, the cytosolic enzyme TrxR1, the mitochondrial enzyme
TrxR2, and a testis-specific enzyme thioredoxin-glutathione
reductase (TGR/TrxR3) [56]. Here, we show that MeHg
treatment inhibited rat TrxR activity in brain, liver, and
kidney (Figure 9). MeHg forms covalent bonds between its
Hg moiety and the Se of the selenocysteine of the enzyme,
thus directly inhibiting the activity of TrxR [1]. Since TrxR is
critical for cellular antioxidant defense system the inhibition
o ft h i se n z y m el i k e l yh a sac e n t r a lr o l ei nm e d i a t i n gt h e
toxicity of MeHg.
Recently, diphenyl diselenide was demonstrated to be
a substrate for cerebral and hepatic rat TrxR, which could
account, at least in part, for the antioxidant properties of
(PhSe)2 [23]. Herein, rats treated solely with (PhSe) showed
an increase in the activity of renal TrxR (Figures 9(a) and
9(b), resp.). The formation of selenhidric acid from (PhSe)2
c o u l da l s oe x p l a i nt h ei n c r e a s ei nT r x Ra c t i v i t y ,s i n c et h i s
inorganic form of Se can be converted to selenocysteine
and incorporated to selenoenzymes, such as TrxR [45,
57]. Accordingly, Zhang et al. [58] have demonstrated that
organoselenium compounds (including diselenide) increase
t h ee x p r e s s i o no fT r x Ri nw h i t eb l o o dc e l l sl i n e si nc u l t u r e .
The cotreatment with (PhSe)2 and MeHg was ineffective in
attenuating the inhibition of MeHg-induced TrxR in liver,
kidney, and brain (Figure 9). Similarly, studies in vitro and
in vivo have previously corroborated that selenite was able
to recover the activity of HgCl2-induced TrxR inhibition but
not in response to MeHg. The effect of Se (as selenide) was
attributed to the displacement of Hg from the active site,
giving rise to mercury selenide and regenerating the TrxR
selenol [1, 9].
5. Conclusions
In conclusion, the results of this study established that
(PhSe)2 can increase Hg body burden (likely associated with
release of inorganic Se from (PhSe)2) and MeHg neurotoxic-
ityinra tsdesp itethefacttha t(PhSe) 2 bluntedthedeleterious
effects of MeHg on thiol levels. The results presented herein
alsoreinforcethecentralroleofmitochondrialdysfunctionin
mediating the aberrant effects of MeHg in vivo,a sw e l la st h e
roleofTrxRasamoleculartargetforMeHgintherat.Further
research into MeHg-(PhSe)2 interactions will be helpful in
characterizing the consequences concomitant exposures to
t h e s ea n dr e l a t e dc o m p o u n d s .BioMed Research International 11
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